CareDx Receives Award for Introducing RemoTraC During Pandemic and Sponsoring the Honor the Gift Coalition for Successful Passage of the Immuno Bill
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C.
“The National Kidney Foundation is proud to present CareDx with our corporate citizenship award,” said Kevin Longino, chief executive officer of the National Kidney Foundation and a kidney transplant recipient. “They were a key ally on our legislative efforts to expand Medicare coverage of immunosuppressive drugs, and their commitment to patients is remarkable. CareDx continues to strive for the best outcomes by keeping transplant patients at the center of all they do. We are honored to recognize their contributions to the transplant community."
Reg Seeto, CEO and President of CareDx, accepted the award in recognition of RemoTraC®, a mobile phlebotomy testing service introduced during the height of the COVID-19 pandemic. RemoTraC is offered to all patients who want their transplant monitoring lab tests to be drawn from the comfort of their homes by trained mobile phlebotomists.
Said Reg Seeto, “Patient safety is one of our top priorities and immunosuppressed transplant patients are among the most vulnerable and were at highest risk during the pandemic. It was critical that we quickly mobilize our efforts to offer mobile phlebotomy testing services for AlloSure® and AlloMap® testing in the safety of a patient’s home. Resources at hospitals at the time were also preoccupied with serving COVID-19 patients, so we were also helping to reduce the clinician burden at the time which was overwhelming.”
Peter Maag, former CEO and CareDx board member, joined Mr. Seeto in receiving the award for his leadership in mobilizing the transplant community to advocate for the successful passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (Immuno Bill). The Immuno Bill became effective on January 1, 2023.
“We were compelled to take a stand and advocate for legislation through the company’s sponsorship of the Honor the Gift Coalition to extend Medicare coverage of immunosuppression medication beyond the current three-year cap,” said Peter Maag. “This was a defining moment in my life’s work, and I am extremely proud for what we accomplished together as we stood united in our fight to help kidney transplant patients.”
About the Honor the Gift Coalition
In March 2019, driven by its dedication to serving transplant patients and caregivers, CareDx launched the Honor the Gift Coalition – a national patient-centered campaign focused on rallying the kidney community for the passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (Immuno Bill). With 32 coalition partners across the transplant, donor, and kidney community, including the National Kidney Foundation, the American Society of Transplant Surgeons, and Donate Life America, the Coalition successfully united and encouraged nearly 10,000 advocates from all 50 states to write to their legislators and demand their support for this critical legislation. For more information about the Coalition, please visit: www.honorthegift.org/coalition.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s testing services, AlloSure, AlloMap and RemoTraC. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its testing services, including AlloSure, AlloMap and RemoTraC; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.